Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

nger patients. In the Phase 1 trial, voreloxin was administered on a weekly or twice-weekly schedule and patient demographics were similar between the two treatment schedules. Six patients, including four age 60 or older and two younger than age 60, achieved complete remission (CR) or complete remission without platelet recovery (CRp) or complete remission with incomplete recovery of hematopoeitic elements (CRi) when voreloxin was administered at doses of 50 mg/m2 or greater weekly or 40 mg/m2 twice-weekly. Duration of complete remissions (CR or CRp) was reported. Remissions of up to seven months have been observed thus far, with two patients undergoing reinduction with voreloxin following relapse.

Sixty-eight patients were evaluable for safety, with 42 patients ranging in age from 60-85 years old and 26 patients age 21-59 years. Voreloxin was generally well tolerated in both the older and younger patient subgroups with similar incidence of Grade 3-4 adverse events. The dose-limiting toxicity was reversible oral mucositis, and a maximum-tolerated dose of 72 mg/m2 once-weekly and 40 mg/m2 twice-weekly was established. Researchers also reported that voreloxin pharmacokinetics were not influenced by age.

"AML is primarily a disease of the elderly and the medical need for new agents that can be tolerated by older patients remains unmet. Results from our comparative analysis demonstrate that voreloxin is generally well tolerated and achieves anti-leukemic activity among older, advanced AML patients, supporting our strategy for progressing the clinical development of voreloxin in this indication," said Glenn Michelson, M.D., Vice President, Clinical Strategy at Sunesis. "Sunesis recently initiated the Phase 2 REVEAL-1 (Response Evaluation of Voreloxin in Elderly AML) clinical trial to evaluate voreloxin in newly diagnosed AML in elderly patients. We hope to present initial data from the REVEAL-1 trial later this year."

Preliminary Data from Phase 1b S
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Ohio and MELVILLE, N.Y. ... CAH ), one of the world,s largest ... HSIC ), the world,s largest provider of ... health and medical practitioners, today announced that the companies ... one of the most comprehensive service and product offerings ...
(Date:11/21/2014)... 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or ... Todd Martensen has been ... role of Chief Commercial Officer, to oversee KLOX,s commercial ... gel for the treatment of chronic and other hard-to-heal ... approved in Europe . Mr. Martensen, ...
(Date:11/21/2014)... Oxis International, Inc. (OXIS) (OXI.PA) announced today the ... Anthony J. Cataldo as Chief Executive Officer, and ... 2014, Ken Eaton resigned his positions as Chief ... Oxis International, Inc. to pursue new opportunities. Mr. ... Officer of Oxis International, Inc. Mr. Cataldo will continue to ...
Breaking Medicine Technology:Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
... 12, 2011 Varian Medical Systems, Inc. (NYSE: ... technology for treating cancer with radiotherapy, and privately-held Augmenix, ... under which Varian will make a $15 million minority ... hydrogel products to improve outcomes in radiation oncology.  The ...
... 12, 2011 Polaris Group (Polaris) today announced that ... Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a ... China Standard Time in Taipei, Taiwan. Details ... ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented ...
Cached Medicine Technology:Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 2Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 3Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 4Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 2Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 3
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... The topic of B&D Rockeries’ latest publication ... The article states that, “While they give off the appearance ... go into creating this powerful look.” , One of the ... choosing which kind of block matches your home environment and ... “The two main options are concrete and stone blocks. But ...
(Date:11/22/2014)... Forbes Living TV and featured ... that Ashley Lombardo and friend Candy Sherman are the ... Lombardo entered friend Candy Sherman to receive a generous ... her friend is courageously battling lung cancer and raising ... medical bills piling up and the constant struggle to ...
(Date:11/22/2014)... 2014 “Greenfield Naturals” was featured on ... , which features the latest and coolest technology products ... reporter for NewsWatch, conducted the product review and shared ... of your water. , From pollution to hazardous substances ... everything is done to remove these chemicals, especially in ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... to Improve Patient Care, LYNWOOD, Calif., Sept. ... have reached a tentative agreement on a new ... their ability to,advocate for improved patient care, as ... and skilled staff. The agreement, which must ...
... Sept. 7 Rocky Vista,University College of ... the,28 colleges of osteopathic medicine in the ... medicine in Colorado, has been granted provisional,accreditation ... College Accreditation (AOA-COCA). The provisional accreditation,will allow ...
... Texas, Sept. 7 Concentra ("Concentra" or the,"Company"), ... established,an on-site medical clinic at the construction site ... The clinic offers construction workers a,convenient way to ... the World Trade Center site treat construction,personnel, building ...
... higher material prices. ... the year., ST. LOUIS, Sept. 7 Allied Healthcare,Products, ... increased 38,percent to $869,000, or 11 cents per share, during ... cents per share, for the fourth,quarter last year. Despite ...
... Sept. 7 AdvaMed General Counsel,Christopher White issued ... H.R. 1908, The Patent Reform Act of 2007:, ... House of Representatives,demonstrates the significant bipartisan opposition to ... important patent protections by,making patents easier to challenge ...
... 7 VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ... minimally invasive treatment of venous reflux disease, today,announced ... Officer,and Vice President, Finance & Administration, to be ... VNUS has begun a search for a,new chief ...
Cached Medicine News:Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Colorado Medical School Receives Provisional Accreditation 2Health News:Colorado Medical School Receives Provisional Accreditation 3Health News:Concentra Opens On-Site Medical Unit at World Trade Center Site 2Health News:Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006 2Health News:Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006 3Health News:Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006 4Health News:Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006 5
Inquire...
Holligard protects skin from irritating stomal discharge. Holligard is flexible and durable in heat and humidity....
Security and confidence assured with porous tape; integral deodorizing/venting filter....
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an...
Medicine Products: